Genetic Basis of Rosacea

Validation of Candidate Rosacea Genes By Targeted Interrogation of Alleles and Assessment of Rosacea Co-morbidities

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02787616

Enrollment

306

Registered

2016-06-01

Start date

2012-04-13

Completion date

2018-11-16

Last updated

2019-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.

Interventions

GENETICbuccal swab

cheek swab for DNA sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Eligibility Criteria for Rosacea Group: Inclusion criteria for rosacea participants: 1. Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator 2. All four grandparents of European descent 3. Fitzpatrick skin type I or II 4. Age 18 years or older

Exclusion criteria

for rosacea participants: 1. Unable or unwilling to provide written informed consent 2. Concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus) 3. Acne vulgaris 4. Unable or unwilling to provide peripheral blood sample (a few teaspoons) 5. Inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.) 6. Use of topical prescription medications or procedures to the face within one month of enrollment 7. Women who are pregnant or lactating Eligibility Criteria for Non-Rosacea Group: Inclusion criteria for control participants: 1. No history of rosacea 2. No clinical signs or symptoms of rosacea 3. No family history of rosacea 4. All four grandparents of European descent 5. Fitzpatrick skin type I or II 6. Age 18 years or older

Design outcomes

Primary

Measure	Time frame
Targeted interrogation of alleles and assessment of rosacea co-morbidities.	Up to 2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026